| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 5,080 | 5,336 | ||
| General and administrative | 967 | 1,000 | ||
| Total operating expenses | 6,047 | 6,336 | ||
| Loss from operations | -6,047 | -6,336 | ||
| Interest income | 1,427 | 1,530 | ||
| Interest expense | 0 | 0 | ||
| Other (expense) income | -85 | -3 | ||
| Foreign exchange gain (loss) | -1,201 | 3,081 | ||
| Total other income | 141 | 4,608 | ||
| Loss before income taxes | -5,906 | -1,728 | ||
| Income tax (expense) benefit | 102 | 28 | ||
| Net loss | -6,008 | -1,756 | ||
| Net loss per sharebasic and diluted (in dollars per share) | -0.2 | -0.06 | ||
| Shares used to compute basic and diluted net loss per share (in shares) | 30,487,731 | 30,487,731 | ||
XBiotech Inc. (XBIT)
XBiotech Inc. (XBIT)